Notícias

NVO's Sogroya wins a positive CHMP opinion for idiopathic short stature in the EU, potentially broadening its pediatric growth disorder reach.

On this episode of Stock Movers: - Novo Nordisk (NVO) shares are lower as it disappointed investors hoping for concrete turnaround plans from Chief Executive Officer Mike Doustdar after losing its lead in the obesity market to Eli Lilly & Co. The company pledged to launch more than five blockbusters and deliver more than $23 billion in new sales in coming years, but investors are selling shares due to lack of concrete news. - Arhaus (ARHS) is moving after Jefferies upgraded the furniture company to buy from hold, writing that it has "newfound optimism on the retailer's strategy to elevate brand awareness" and improve market share. - Accenture (ACN) is up on news Anthropic is partnering with Accenture to test the safety of its advanced artificial intelligence models by embedding evaluators from the consulting firm directly within its operations.

Yahoo Finance Executive Editor Brian Sozzi outlines a few unexpected events driving markets this week. For a closer look, watch the video above.

Novo Nordisk (NVO) stock is dipping after the company's outlook disappointed investors. Yahoo Finance Executive Editor Brian Sozzi shares his thoughts on the stock, the company's trajectory, and where Eli Lilly (LLY) fits into the equation.

Novo Nordisk took the stage at its own capital markets day and said something that sent its stock tumbling 7%, yet its closest rivals barely flinched. What the company revealed about its future tells investors exactly how much trouble the Ozempic empire may be in.

The 8:30 panel featuring Yahoo Finance Host Julie Hyman, Senior Autos Reporter Pras Subramanian, and Breaking Business News Reporter Jake Conley examines Novo Nordisk’s (NVO ) long-term targets as shares slide amid intensifying competition from Eli Lilly (LLY ).

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.7% and the actively trad

Novo Nordisk plans to launch at least five multi-blockbuster drugs by 2030 and is targeting pipeline drug sales of $23 billion by 2035.

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

Warner Bros. Discovery and Paramount Skydance shares rose in premarket trading as investors focused on the merger talks.

Novo Nordisk Stock Gets Hit Despite Massive Obesity Sales Goal and New Drug Planswsazz

The drugmaker expects growth in line with industry peers as it works to rebuild its pipeline beyond obesity

Novo Nordisk’s long-term growth targets failed to ease investor concerns over Eli Lilly’s obesity-drug lead, CagriSema’s comparative performance and upcoming semaglutide patent expirations.

The Danish drugmaker pledged to launch 5 multi-blockbuster drugs by 2030 and grow revenue in line with peers, but investors wanted more

Shares in the company fell more than 4% as its CEO laid out plans for new blockbuster drugs in the next few years.

Novo Nordisk (NYSE:NVO) shares declined 6% on Monday after the Danish pharmaceutical company presented its long-term strategy and financial ambitions at a capital markets day in London. The company expects compound annual revenue growth between 2026 and 2030 to be in line with that of its industry peers, while maintaining a broadly stable operating margin.

Novo Nordisk shares plunged in early trading as the company pledged to launch more than five blockbuster drugs and deliver more than $23 billion in new sales in coming years. The plans disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly. Bloomberg's Sanne Wass reports.

Novo Nordisk (NVO) shares are slimming down.

Novo Nordisk (NVO) shares are slimming down.

Novo Nordisk (NVO) shares are slimming down.

Shares in Novo Nordisk fell more than 4% as its CEO laid out plans to launch new blockbuster drugs in the next few years while expanding into further treatment areas.

Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday.

Morgan Stanley has cut Novo Nordisk A/S (NYSE:NVO) to Underweight on September 11, 2026. Semaglutide, the underlying molecule for Wegovy and Ozempic, generates roughly 75% of 2026 revenue. Morgan Stanley models that it will still represent 59% of total sales when its patent protection expires in 2031. And according to the firm, the valuation does […]

Lexicon Pharmaceuticals (NASDAQ:LXRX) said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027. Speaking at the H.C. Wainwright 28th Annual Global Investment Conference, Chief Executiv

Investing.com -- European assets may offer investors advantages that are being overlooked as markets remain heavily focused on U.S. technology leadership, according to Macquarie Global Strategy, which sees structural changes supporting stronger European returns.

Ascendis Pharma (NasdaqGS:ASND) has regained exclusive rights to TransCon technology-based products in metabolic and cardiovascular diseases after ending its collaboration with Novo Nordisk. The company plans to advance its own programs in obesity and type 2 diabetes using its TransCon platform. Management highlighted once-monthly TransCon Semaglutide as a planned program within its expanded metabolic disease pipeline. The regained TransCon metabolic and cardiovascular rights and plans for...

The consumer health company’s GLP-1 shelf strategy at CVS is paying off, and bigger retailers could follow.

Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble on incremental gains.

Novo Nordisk A/S (NYSE:NVO) decision to use “Novo” as its day-to-day name is part of a broader attempt by CEO Mike Doustdar to reset the company’s culture and sharpen its competitive focus. The rebrand comes as Novo tries to regain momentum in obesity drugs after losing ground to Eli Lilly. Doustdar’s new “Novo Way” emphasizes […]

Novo (formerly Novo Nordisk) is partnering with Anthropic to use AI to speed up drug discovery.